Moderna Slowed Enrollment in Its Phase 3 Coronavirus Vaccine Clinical Trial

In the last week, Moderna (NASDAQ:MRNA) substantially slowed enrollment in the phase 3 clinical trial testing its coronavirus vaccine, mRNA-1273. After a slight slowdown last week, the biotech took a major breather, enrolling just over half the number of participants it had enrolled in the previous week.